Stock Research for BCRX


Featured Broker: Ally Invest

Get the due diligence for another stock.


BCRX Stock Chart & Research Data

The BCRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BCRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BCRX Due diligence Resources & Stock Charts

The BCRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BCRX Detailed Price Forecast - CNN Money CNN View BCRX Detailed Summary - Google Finance
Yahoo View BCRX Detailed Summary - Yahoo! Finance Zacks View BCRX Stock Research & Analysis -

Stock Analysis

TradeIdeas View BCRX Trends & Analysis - Trade-Ideas Barrons View BCRX Major Holders - Barrons
NASDAQ View BCRX Call Transcripts - NASDAQ Seeking View BCRX Breaking News & Analysis - Seeking Alpha
Spotlight View BCRX Annual Report - OTC Report View BCRX OTC Short Report -
TradeKing View BCRX Fundamentals - TradeKing Charts View BCRX SEC Filings - Bar Chart
WSJ View Historical Prices for BCRX - The WSJ Morningstar View Performance/Total Return for BCRX - Morningstar
MarketWatch View the Analyst Estimates for BCRX - MarketWatch CNBC View the Earnings History for BCRX - CNBC
StockMarketWatch View the BCRX Earnings - StockMarketWatch MacroAxis View BCRX Buy or Sell Recommendations - MacroAxis
Bullish View the BCRX Bullish Patterns - American Bulls Short Pains View BCRX Short Pain Metrics -

Social Media Mentions

StockTwits View BCRX Stock Mentions - StockTwits PennyStocks View BCRX Stock Mentions - PennyStockTweets
Twitter View BCRX Stock Mentions - Twitter Invest Hub View BCRX Investment Forum News - Investor Hub
Yahoo View BCRX Stock Mentions - Yahoo! Message Board Seeking Alpha View BCRX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BCRX - Insider Cow View Insider Transactions for BCRX - Insider Cow
CNBC View BCRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BCRX - OTC Markets
Yahoo View Insider Transactions for BCRX - Yahoo! Finance NASDAQ View Institutional Holdings for BCRX - NASDAQ

Stock Charts

FinViz View BCRX Stock Insight & Charts - StockCharts View BCRX Investment Charts -
BarChart View BCRX Stock Overview & Charts - BarChart Trading View View BCRX User Generated Charts - Trading View

Latest Financial News for BCRX

Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT
Posted on Monday December 17, 2018

Q3 2018 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up
Posted on Sunday December 16, 2018

It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
Posted on Tuesday November 27, 2018

NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
Posted on Tuesday November 20, 2018

BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. At Shire, Ms. Heggie also built the EMEA rare disease business from $96 million to more than $750 million, and served as chief executive officer of Jerini, following Shire’s acquisition of the company, and its lead asset, Firazyr®, for the treatment of hereditary angioedema (HAE).

Stock Market & Investing Books

Enter a stock symbol to view the stock details.